Bupropion is a nicotinic antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 295, Issue 1, 2000, Pages 321-327

  Slemmer, J E ^a   Martin, B R ^a   Damaj, M I ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE; NICOTINIC RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTICONVULSANT ACTIVITY; ANTINOCICEPTION; ARTICLE; CENTRAL NERVOUS SYSTEM; CONCENTRATION RESPONSE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HYPOTHERMIA; MALE; MOUSE; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RECEPTOR BLOCKING;

ANIMAL; BUPROPION; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; NICOTINE; NICOTINIC ANTAGONISTS; RECEPTORS, NICOTINIC; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0033798742     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Optically pure (+)-nicotine from (±)-nicotine and biological comparisons with (-)-nicotine
2. Bupropion: A review of its mechanism of antidepressant activity
3. The search for less harmful analgesics
4. Relationship between bupropion disposition and dopamine uptake inhibition in rats and in mice
5. Evidence that the acute behavioral and electrophysiological effects of bupropion (Welbutrin) are mediated by a noradrenergic mechanism
6. Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice
7. Pharmacological characterization of nicotine-induced seizures in mice
8. Pharmacological characterization of nicotine's interaction with cocaine and cocaine analogs
9. A method for determining loss of pain sensation
10. The effect of various neurohormonal modulations on the activity of morphine and the narcotic antagonists in tail-flick and phenylquinone test
11. Synthetic analgesics. II. Dithienybutenyl- and benzomorphans
12. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects
13. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine and ibogaine
14. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression
15. A comparison of sustained-release bupropion and placebo for smoking cessation
16. Intrathecal morphine in mice: A new technique
17. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers
18. Antidepressant profile of bupropion and three metabolites in mice
19. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits
20. ++-insensitive mutants
21. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone
22. 3H]nicotine binding to mouse brain homogenate
23. Rate of binding of various inhibitors at the dopamine transporter in vivo
24. Pharmacokinetic of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs
25. Pharmacological significance of the species differences in bupropion metabolism